Display options
Cite
Poggi G, Villani L, Sottotetti F, et al. Treatment of chronic hepatitis C in a patient affected by systemic sclerosis. Gastroenterol Res Pract. 2009;2009:475390doi: 10.1155/2009/475390.
Poggi, G., Villani, L., Sottotetti, F., Tagliaferri, B., Montagna, B., Amatu, A., & Bernardo, G. (2009). Treatment of chronic hepatitis C in a patient affected by systemic sclerosis. Gastroenterology research and practice, 2009475390. https://doi.org/10.1155/2009/475390
Poggi, Guido, et al. "Treatment of chronic hepatitis C in a patient affected by systemic sclerosis." Gastroenterology research and practice vol. 2009 (2009): 475390. doi: https://doi.org/10.1155/2009/475390
Poggi G, Villani L, Sottotetti F, Tagliaferri B, Montagna B, Amatu A, Bernardo G. Treatment of chronic hepatitis C in a patient affected by systemic sclerosis. Gastroenterol Res Pract. 2009;2009:475390. doi: 10.1155/2009/475390. Epub 2009 Nov 17. PMID: 19997512; PMCID: PMC2786055.
Copy Download .nbib Format: NLM
Share it on

Gastroenterol Res Pract. 2009;2009:475390. doi: 10.1155/2009/475390. Epub 2009 Nov 17.

Treatment of chronic hepatitis C in a patient affected by systemic sclerosis.

Gastroenterology research and practice

Guido Poggi, Laura Villani, Federico Sottotetti, Barbara Tagliaferri, Benedetta Montagna, Alessio Amatu, Giovanni Bernardo

Affiliations

  1. Department of Oncology, IRCCS Maugeri Foundation, via Maugeri 8, 27100 Pavia, Italy. [email protected]

PMID: 19997512 PMCID: PMC2786055 DOI: 10.1155/2009/475390

Abstract

The currently recommended treatment for patients infected with hepatitis C virus (HCV) is pegilated interferon alpha (IFN alpha) plus ribavirin. Despite the numerous benefits of this therapy, there is an increasing concern regarding his tolerance. Among the most common side effects, interferon may trigger the onset or exacerbation of autoimmune diseases. When chronic hepatitis C coexists with an autoimmune disorder, it is not clear whether using interferon is better than avoiding it. We evaluated the disease state of a 55-year old female affected by sistemic sclerosis (SSc), during and after therapy with IFNalpha pegilated plus ribavirin for chronic HCV infection. We were worried about the potential worsening of the autoimmune disease during the therapy, but we were confident that we would give our patient a short course of peginterferon and ribavirin. A mild, asymptomatic worsening of lung SSc was observed during IFN administration, without life threatening symptoms. After 24 months follow up we observed the maintenance of the virological response and a good control of the rheumatological disease. Thus, in liver disease at high risk of progression and concomitant SSc, the antiviral therapy with IFNalpha is a feasible approach.

References

  1. Hepatology. 2002 Nov;36(5 Suppl 1):S237-44 - PubMed
  2. Autoimmunity. 2003 Dec;36(8):511-8 - PubMed
  3. Curr Opin Investig Drugs. 2006 May;7(5):451-6 - PubMed
  4. Annu Rev Immunol. 2005;23:307-36 - PubMed
  5. J Rheumatol. 1996 Apr;23(4):654-8 - PubMed
  6. Intern Med. 2007;46(8):473-6 - PubMed
  7. Rheumatology (Oxford). 2005 Aug;44(8):1016-20 - PubMed
  8. Hepatology. 1993 Oct;18(4):998-1005 - PubMed
  9. N Engl J Med. 1991 Apr 4;324(14):933-40 - PubMed
  10. Clin Exp Rheumatol. 2001 Mar-Apr;19(2):197-200 - PubMed
  11. Arthritis Rheum. 2003 May;48(5):1363-73 - PubMed
  12. Br J Dermatol. 2002 Aug;147(2):385-6 - PubMed
  13. N Engl J Med. 2005 Jun 23;352(25):2609-17 - PubMed
  14. Hepatology. 2002 Nov;36(5 Suppl 1):S226-36 - PubMed
  15. J Immunol. 2002 Apr 1;168(7):3649-59 - PubMed
  16. Gut. 2005 Mar;54(3):402-6 - PubMed
  17. J Viral Hepat. 2002 Jan;9(1):71-4 - PubMed
  18. Hepatology. 2004 Apr;39(4):1147-71 - PubMed
  19. Am J Med. 2003 Oct 1;115(5):390-7 - PubMed
  20. J Clin Invest. 1987 May;79(5):1318-24 - PubMed
  21. Arthritis Rheum. 1999 Feb;42(2):299-305 - PubMed
  22. Clin Exp Rheumatol. 2000 Sep-Oct;18(5):579-84 - PubMed
  23. Clin Exp Rheumatol. 2004 Sep-Oct;22(5):625-8 - PubMed

Publication Types